<DOC>
	<DOCNO>NCT01532869</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , two-arm , parallel-group study evaluate efficacy safety RoActemra/Actemra ( tocilizumab ) participant systemic sclerosis . Participants randomize receive either RoActemra/Actemra 162 mg subcutaneously weekly placebo 48 week . From Week 48 Week 96 , participant receive open-label RoActemra/Actemra 162 mg subcutaneously weekly . Anticipated time study treatment 96 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Versus Placebo Patients With Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Systemic sclerosis , define American College Rheumatology ( 1980 ) criterion Disease duration &lt; /= 60 month ( defined time first nonRaynaud phenomenon manifestation ) &gt; /= 15 &lt; /= 40 mRSS unit screen Active disease , define protocol Uninvolved skin injection sit Negative pregnancy test female subject childbearing potential Major surgery ( include joint surgery ) within 8 week prior and/or study enrollment Rheumatic autoimmune disease systemic sclerosis Skin thickening ( scleroderma ) limit area distal elbow knee screen Previous treatment tocilizumab History severe allergic anaphylactic reaction human , humanize , murine monoclonal antibody Severe cardiopulmonary disease Known active current history recurrent infection Use investigational , biologic , immunosuppressive therapy include intraarticular parenteral corticosteroid prior study enrollment specify protocol As specify protocol , current past medical condition medical history involve limited nervous , renal , pulmonary , endocrine , gastrointestinal organ system determine Principal Investigator pose significant safety risk subject participate study Primary secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>